Wedbush Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains a Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) and lowers the price target from $67 to $57.
April 17, 2024 | 4:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wedbush has maintained a Neutral rating on Apellis Pharmaceuticals and reduced the price target from $67 to $57.
The reduction in price target by a reputable analyst like Laura Chico from Wedbush could lead to a negative short-term sentiment among investors, potentially causing a decrease in the stock price of Apellis Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100